Setia Vishwas, the Chief Financial Officer of MapLight Therapeutics, Inc. (NASDAQ:MPLT), reported the sale of 2,922 shares of Voting Common Stock in transactions conducted on April 15 and April 16, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission.
The filings show the total proceeds from the trades were $78,572, with execution prices spanning from $26.87 to $27.49. The breakdown of the reported transactions is as follows:
- April 15, 2026 - 2,806 shares sold at $26.87;
- April 16, 2026 - 29 shares sold at $27.01;
- April 16, 2026 - 87 shares sold at $27.49.
Following these dispositions, the filing indicates that Setia Vishwas directly holds 392,627 shares of MapLight Therapeutics. The reported sales were carried out to meet statutory tax withholding obligations associated with the vesting of restricted stock units.
Market activity since the disclosed sales shows the stock rising to $30.05, trading close to a 52-week high of $31.13, and the shares have climbed 71% year-to-date.
Separately, analysis from InvestingPro cited in the filing notes that MapLight’s shares currently appear overvalued relative to the service’s Fair Value assessment, and that InvestingPro provides 12 additional exclusive tips for MPLT covering the company’s financial health and momentum indicators.
Analyst coverage of MapLight has also been active. TD Cowen initiated coverage with a buy rating, calling attention to MapLight’s pipeline of treatments intended for central nervous system and neuropsychiatric disorders and specifically highlighting the lead asset, ML-007C-MA, which is designed to improve the treatment profile for schizophrenia. The firm noted Phase II data for that candidate is anticipated in the third quarter of this year.
Stifel reiterated its buy rating and kept a $28.00 price target following MapLight’s fourth-quarter update. In its commentary, Stifel pointed out that phase 2 data for ML-007C-MA remain on schedule for a topline readout in the third quarter of 2026 and expressed interest in potential differentiation on tolerability, safety, or dosing frequency.
These disclosed insider sales, the stock’s recent price performance, and the analyst attention on the company’s lead candidate together reflect ongoing market and investor focus on MapLight Therapeutics and its clinical timelines.